Brian R. Baer

2.6k total citations
17 papers, 459 citations indexed

About

Brian R. Baer is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Brian R. Baer has authored 17 papers receiving a total of 459 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Oncology and 9 papers in Pharmacology. Recurrent topics in Brian R. Baer's work include Pharmacogenetics and Drug Metabolism (9 papers), Drug Transport and Resistance Mechanisms (5 papers) and Pancreatic function and diabetes (3 papers). Brian R. Baer is often cited by papers focused on Pharmacogenetics and Drug Metabolism (9 papers), Drug Transport and Resistance Mechanisms (5 papers) and Pancreatic function and diabetes (3 papers). Brian R. Baer collaborates with scholars based in United States, Australia and Belgium. Brian R. Baer's co-authors include Allan E. Rettie, Kirk R. Henne, Andrew C. Allen, Robert Kirk DeLisle, Larry C. Wienkers, Dan A. Rock, Kent L. Kunze, Matthew James Cheesman, Eric F. Johnson and Mei‐Hui Hsu and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Biochemistry.

In The Last Decade

Brian R. Baer

17 papers receiving 449 citations

Peers

Brian R. Baer

PHARM

ONCOL

BIOCH

CTM

F. Peter Guengerich United States

Andrew P. Blanchard United States

Dayong Si China

Hsia-lien Lin United States

Paul Toren United States

Chitra Sridar United States

Katsuhiro Ohyama Japan

Yasushi Yoshigae Japan

Steven J. Pernecky United States

J. C. Bloomer United Kingdom

F. Peter Guengerich United States

Brian R. Baer

362 ×1.3

PHARM

261 ×1.5

189 ×1.4

ONCOL

74 ×0.8

BIOCH

46 ×0.8

CTM

Citations per year, relative to Brian R. Baer Brian R. Baer (= 1×) peers F. Peter Guengerich

Countries citing papers authored by Brian R. Baer

Since Specialization

Citations

This map shows the geographic impact of Brian R. Baer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian R. Baer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian R. Baer more than expected).

Fields of papers citing papers by Brian R. Baer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian R. Baer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian R. Baer. The network helps show where Brian R. Baer may publish in the future.

Co-authorship network of co-authors of Brian R. Baer

This figure shows the co-authorship network connecting the top 25 collaborators of Brian R. Baer. A scholar is included among the top collaborators of Brian R. Baer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian R. Baer. Brian R. Baer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Baer, Brian R., Karin Brown, Matthew G. McDonald, et al.. (2025). Novel O-methylpyrimidine prodrugs of phenolic compounds bioactivated by aldehyde oxidase: Enhancing metabolic stability against first-pass conjugative metabolism in the intestine. Drug Metabolism and Disposition. 53(4). 100059–100059. 1 indexed citations

Ren, Li, David Moreno‐Mateos, Brian R. Baer, et al.. (2024). Identification of the Clinical Candidate PF-07284890 (ARRY-461), a Highly Potent and Brain Penetrant BRAF Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry. 67(15). 13019–13032. 1 indexed citations

Marx, Matthew A., Brian R. Baer, Joshua A. Ballard, et al.. (2020). Abstract B30: Structure-based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer. Molecular Cancer Research. 18(5_Supplement). B30–B30. 5 indexed citations

Hinklin, Ronald J., Brian R. Baer, Steven A. Boyd, et al.. (2019). Discovery and preclinical development of AR453588 as an anti-diabetic glucokinase activator. Bioorganic & Medicinal Chemistry. 28(1). 115232–115232. 10 indexed citations

Christensen, James G., Jay B. Fell, Jill Hallin, et al.. (2019). Abstract C069: The identification of MRTX849, a novel KRASG12C inhibitor under clinical investigation, provides insight toward therapeutic susceptibility of KRAS mutant cancers. Molecular Cancer Therapeutics. 18(12_Supplement). C069–C069. 5 indexed citations

Christensen, James G., Jay B. Fell, Matthew A. Marx, et al.. (2019). Abstract LB-271: Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257, a novel KRAS G12C mutant selective small molecule inhibitor. Cancer Research. 79(13_Supplement). LB–271. 7 indexed citations

Hsu, Mei‐Hui, Brian R. Baer, Allan E. Rettie, & Eric F. Johnson. (2017). The Crystal Structure of Cytochrome P450 4B1 (CYP4B1) Monooxygenase Complexed with Octane Discloses Several Structural Adaptations for ω-Hydroxylation. Journal of Biological Chemistry. 292(13). 5610–5621. 43 indexed citations

Lü, Min, Pingping Li, Gautam Bandyopadhyay, et al.. (2014). Characterization of a Novel Glucokinase Activator in Rat and Mouse Models. PLoS ONE. 9(2). e88431–e88431. 16 indexed citations

Hinklin, Ronald J., Thomas D. Aicher, Deborah Anderson, et al.. (2014). Discovery of 2-Pyridylureas as Glucokinase Activators. Journal of Medicinal Chemistry. 57(19). 8180–8186. 17 indexed citations

10.

Baer, Brian R., Robert Kirk DeLisle, & Andrew C. Allen. (2009). Benzylic Oxidation of Gemfibrozil-1-O-β-Glucuronide by P450 2C8 Leads to Heme Alkylation and Irreversible Inhibition. Chemical Research in Toxicology. 22(7). 1298–1309. 65 indexed citations

11.

Baer, Brian R., Larry C. Wienkers, & Dan A. Rock. (2007). Time-Dependent Inactivation of P450 3A4 by Raloxifene: Identification of Cys239 as the Site of Apoprotein Alkylation¹. Chemical Research in Toxicology. 20(6). 954–964. 62 indexed citations

12.

Baer, Brian R., Kent L. Kunze, & Allan E. Rettie. (2007). Mechanism of Formation of the Ester Linkage between Heme and Glu310 of CYP4B1: ¹⁸O Protein Labeling Studies. Biochemistry. 46(41). 11598–11605. 10 indexed citations

13.

Baer, Brian R. & Allan E. Rettie. (2006). CYP4B1: An Enigmatic P450 at the Interface between Xenobiotic and Endobiotic Metabolism. Drug Metabolism Reviews. 38(3). 451–476. 74 indexed citations

14.

Baer, Brian R., Allan E. Rettie, & Kirk R. Henne. (2005). Bioactivation of 4-Ipomeanol by CYP4B1: Adduct Characterization and Evidence for an Enedial Intermediate. Chemical Research in Toxicology. 18(5). 855–864. 53 indexed citations

15.

Baer, Brian R., Jason T. Schuman, A. Patricia Campbell, et al.. (2005). Sites of Covalent Attachment of CYP4 Enzymes to Heme: Evidence for Microheterogeneity of P450 Heme Orientation. Biochemistry. 44(42). 13914–13920. 19 indexed citations

16.

Cheesman, Matthew James, et al.. (2003). Rabbit CYP4B1 engineered for high-level expression in Escherichia coli: ligand stabilization and processing of the N-terminus and heme prosthetic group. Archives of Biochemistry and Biophysics. 416(1). 17–24. 41 indexed citations

17.

Baer, Brian R., et al.. (2003). Covalent Heme Binding to CYP4B1 via Glu310 and a Carbocation Porphyrin Intermediate. Biochemistry. 42(15). 4601–4606. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact